Free Trial

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Corbus Pharmaceuticals logo
$16.66 +0.58 (+3.61%)
(As of 11:30 AM ET)

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Key Stats

Today's Range
$16.08
$16.69
50-Day Range
$15.96
$55.81
52-Week Range
$4.00
$61.90
Volume
76,887 shs
Average Volume
564,982 shs
Market Capitalization
$202.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.86
Consensus Rating
Buy

Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
98th Percentile Overall Score

CRBP MarketRank™: 

Corbus Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 42nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corbus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Corbus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.25) to ($6.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corbus Pharmaceuticals is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corbus Pharmaceuticals is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corbus Pharmaceuticals has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Corbus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    20.17% of the float of Corbus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Corbus Pharmaceuticals has recently decreased by 13.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Corbus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corbus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.17% of the float of Corbus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Corbus Pharmaceuticals has recently decreased by 13.45%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Corbus Pharmaceuticals has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corbus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,003,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corbus Pharmaceuticals' insider trading history.
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Corbus Pharmaceuticals Reports Q3 2024 Financial Results
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
See More Headlines

CRBP Stock Analysis - Frequently Asked Questions

Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of 2024. Since then, CRBP stock has increased by 170.4% and is now trading at $16.33.
View the best growth stocks for 2024 here
.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($1.19) by $0.29.

Corbus Pharmaceuticals' top institutional investors include State Street Corp (4.89%), Geode Capital Management LLC (2.05%), Ikarian Capital LLC and Assenagon Asset Management S.A. (2.07%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian.
View institutional ownership trends
.

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE).

Company Calendar

Last Earnings
8/06/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRBP
Employees
40
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$65.86
High Stock Price Target
$88.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+309.6%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-44,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
($1.56) per share

Miscellaneous

Free Float
11,692,000
Market Cap
$195.85 million
Optionable
Optionable
Beta
2.56

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CRBP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners